Skip to content
Screener

iRadimed IRMD Q4 2025 Annual earnings

Reported February 10, 2026 · Before market open

Revenue$22.7MBeat by $1.1M
EPS$0.54Beat by $0.05
Revenue estimate$21.6M
EPS estimate$0.49

Next report

Nov 2, 2026 (in a month)
Revenue estimate$23.2M
EPS estimate$0.52

Financials

Q4 2025

Income statement

See full
Revenue$22.7M+17.0%
Gross profit$17.0M+15.4%
Operating income$7.1M+22.3%
Net income$6.4M+25.2%
EPS (diluted)$0.50+25.0%

Balance sheet

See full
Cash & equivalents$51.2M-2.1%
Total equity$94.6M+9.0%
Total assets$108.8M+10.6%

Cash flow

See full
Operating cash flow$5.9M-1.1%
CapEx$294.2K-89.5%
Free cash flow$5.6M+76.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.24B+77.5%
P/E55.1×+18.8×
P/S14.8×+5.2×

Profitability

See full
Gross margin76.7%-0.2pp
Operating margin31.2%+1.2pp
Net margin26.8%+0.6pp
FCF margin20.5%-3.6pp

Returns & leverage

See full
Return on equity24.8%+0.5pp
Current ratio8×-0.9×

FAQ

When did iRadimed report Q4 2025 earnings?
iRadimed (IRMD) reported Q4 2025 earnings on February 10, 2026 before market open.
What were iRadimed's Q4 2025 revenue and EPS?
iRadimed reported revenue of $22.7M and eps of $0.54 for Q4 2025.
Did iRadimed beat estimates in Q4 2025?
Revenue beat the consensus estimate of $21.6M by $1.1M. EPS beat the consensus estimate of $0.49 by $0.05.
How did iRadimed's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.0% from $19.4M a year earlier and eps grew 22.7% from $0.44.
Where can I find iRadimed's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-012356) and the 10-K periodic report (0001104659-26-024691) directly on SEC EDGAR. The filing index links above go to sec.gov.